About Nomic Bio

Nomic Bio aims to democratize proteomics by providing robust, high-throughput protein profiling data at an unmatched quality-to-cost ratio. The company offers its nELISA platform, featuring customizable and proteome-wide panels like the Omni 1000, through both direct sales and a comprehensive mail-in analysis service. Nomic Bio primarily serves biopharmaceutical companies and scientific institutions focused on drug development and biomarker discovery in fields like cancer immunotherapy.

Company Classification

Customers

Customer	Success Story	Source
Medical University of South Carolina	Measured hundreds of cytokines and soluble factors simultaneously from precious samples, leveraging Nomic’s comprehensive analysis suite.
University of California, Los Angeles	Utilized Nomic’s high‑throughput proteomics to support personalized cancer therapy via drug screening on patient‑derived tumor organoids.
Nice Try Sign up to Ethos to access the full customer list Sign up to Ethos	Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.	Source
Another Company	Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.	Source
One More Company	Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sunt in culpa qui officia deserunt mollit anim id est laborum.	Source
Nice Try	Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.	Source
Another Company	Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.	Source
One More Company	Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sunt in culpa qui officia deserunt mollit anim id est laborum.	Source